Arca
Skip to content
Tools
Tools

Iga nephropathy

Drug research and approvals for iga nephropathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 69 studies of iga nephropathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 15 drug trials for it since 2013, and FDA has 0 approved and 2 open orphan designations naming it.

  • Recruiting worldwide: 69
  • Trials authorized in Canada: 15
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 69 recruiting on ClinicalTrials.gov ↗

How its trials ended

184 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 41 whose ending is known, 41% met their primary endpoint, 7% missed it and 51% stopped early.

  • Ongoing6636%
  • Completed, result not reported4927%
  • Status unknown2815%
  • Met its primary endpoint179%
  • Stopped: other or unclear84%
  • Stopped: sponsor or business decision74%
  • Stopped: enrollment or feasibility42%
  • Missed its primary endpoint32%
  • Stopped: lack of efficacy21%

Trials authorized in Canada

The 10 newest of 15; search them all in Canada trials
Aug 18, 2026A phase 2, multicenter, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of ARGX-121 sc in adult participants with…ARGX-121argenx USPending
Jan 21, 2026A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary iga nephropathyZigakibart (FUB523)Novartis PharmaceuticalsOngoing
Oct 31, 2025A phase 3 multicenter, randomized, double-blind, placebo controlled trial to evaluate efficacy and safety of mezagitamab (TAK-079) in study participants with…Mezagitamab (TAK-079)Takeda Pharmaceuticals USAOngoing
Dec 13, 2024A phase 3, randomized, double-blind, placebo-controlled study of felzartamab in adults with iga nephropathyFelzartamabBiogenOngoing
Jul 24, 2023A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sefaxersen, an antisense inhibitor of…Sefaxersen (RO7434656)RocheOngoing
Jul 11, 2023A phase 3, randomized, double-blind, placebo-controlled study of BION-1301 in adults with iga nephropathy (the beyond study)BION-1301 (zigakibart)Chinook TherapeuticsOngoing
Feb 11, 2022A phase IIb randomized, double-blinded, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of atacicept in subjects with iga…AtaciceptVera TherapeuticsOngoing
Oct 15, 2021A multicenter rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with primary iga…Iptacopan (LNP023)Novartis PharmaceuticalsClosed
May 28, 2021A double blind, randomized, placebo-controlled, multicenter phase IIa, clinical trial to assess efficacy and safety of the human ANTI-CD38 antibody felzartamab…Felzartamab (MOR202)Human Immunology Biosciences, Inc. (Hi-Bio)Ongoing
Mar 1, 2021A phase 3, randomized, double-blind, placebo-controlled study of atrasentan in patients with iga nephropathy at risk of progressive loss of renal function (the…Atrasentan / Zigakibart (FUB523)Chinook Therapeutics U.S.Ongoing

FDA orphan designations

Approved first, then open designations, newest first
Nov 2, 2004Human monoclonal antibody against platelet-derived growth…To slow the progression of IgA nephropathy and delay kidney failure in patients affected by the disease.CuraGen CorporationDesignated
May 4, 2000Omega-3 (n-3) polyunsaturated fatty acidsTreatment of IgA nephropathy.Pronova Biocare, ASDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.